Fig. 4

Inhibition of in vivo tumor formation from HHUA-SP cells by long-term treatment with sorafenib. A Weight of tumors derived from HHUA-SP or -MP cells 2 weeks after oral treatment with or without sorafenib (soraf and ctrl, respectively). Before treatment, tumors formed 6 weeks after inoculation of HHUA-SP or -MP cells into the subcutaneous tissue of nude mice. Each dot indicates the tumor weight of an individual mouse. Images show representative tumors. *, P < 0.05, based on Student’s t-test. Scale bars, 1 mm. B Immunofluorescence staining of HHUA-SP-derived tumors treated as in A for 2 weeks using antibodies against VM and MDR1. DAPI was used for nuclear staining. Scale bars, 200 μm. C Immunofluorescence staining of HHUA-SP- and -MP-derived tumors treated as in A for 2 weeks using antibodies against VM and Ki67. DAPI was used for nuclear staining. Scale bars, 200 μm. D Weight or volume of tumors derived from HHUA-SP or -MP cells 4 weeks after treatment with or without sorafenib (soraf and ctrl, respectively). Tumor formation was assessed 6 weeks after inoculation of HHUA-SP or -MP cells into the subcutaneous tissue of nude mice. Each dot indicates the tumor weight of an individual mouse. Images show representative tumors. *, P < 0.05, based on Student’s t-test. Scale bars, 1 mm. E Immunofluorescence staining of HHUA-SP-derived tumors treated as in D for 4 weeks using antibodies against vimentin (VM) and MDR1. DAPI was used for nuclear staining. Scale bars, 200 μm. F Immunofluorescence staining of HHUA-SP- and -MP-derived tumors treated as in D for 4 weeks using antibodies against vimentin (VM) and Ki67. DAPI was used for nuclear staining. Scale bars, 200 μm